ES2167609T3 - Formulaciones de quinolona inyectables. - Google Patents

Formulaciones de quinolona inyectables.

Info

Publication number
ES2167609T3
ES2167609T3 ES96935251T ES96935251T ES2167609T3 ES 2167609 T3 ES2167609 T3 ES 2167609T3 ES 96935251 T ES96935251 T ES 96935251T ES 96935251 T ES96935251 T ES 96935251T ES 2167609 T3 ES2167609 T3 ES 2167609T3
Authority
ES
Spain
Prior art keywords
quinolona
injectable
formulations
zinc
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935251T
Other languages
English (en)
Inventor
Wayne Alan Boettner
Peter Connor Canning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2167609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2167609T3 publication Critical patent/ES2167609T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

DISOLUCIONES ACUOSAS FARMACEUTICAS ADECUADAS PARA LA INYECCION A UN HUESPED, QUE POSEEN UNA TOLERANCIA EN EL LUGAR DE INYECCION MEJORADA, COMPRENDEN DANOFLOXACINA O SUS SALES FARMACEUTICAMENTE ACEPTABLES Y UN COMPUESTO DE ZINC O MAGNESIO. EL COMPUESTO DE ZINC NECESITA ADEMAS DE LA PRESENCIA DE UN CO-DISOLVENTE.
ES96935251T 1995-12-21 1996-11-13 Formulaciones de quinolona inyectables. Expired - Lifetime ES2167609T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
ES2167609T3 true ES2167609T3 (es) 2002-05-16

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935251T Expired - Lifetime ES2167609T3 (es) 1995-12-21 1996-11-13 Formulaciones de quinolona inyectables.

Country Status (42)

Country Link
US (1) US5811130A (es)
EP (1) EP0868183B1 (es)
JP (1) JP3416145B2 (es)
KR (1) KR100402570B1 (es)
CN (1) CN1104899C (es)
AP (1) AP706A (es)
AR (1) AR005147A1 (es)
AT (1) ATE212551T1 (es)
AU (1) AU709474B2 (es)
BG (1) BG63933B1 (es)
BR (1) BR9612230A (es)
CA (1) CA2239352C (es)
CO (1) CO4480098A1 (es)
CZ (1) CZ293747B6 (es)
DE (1) DE69618987T2 (es)
DK (1) DK0868183T3 (es)
DZ (1) DZ2146A1 (es)
EG (1) EG24071A (es)
ES (1) ES2167609T3 (es)
GT (1) GT199600098A (es)
HR (1) HRP960607B1 (es)
HU (1) HU227918B1 (es)
IL (1) IL124454A (es)
IS (1) IS2010B (es)
MA (1) MA24035A1 (es)
MX (1) MX9805026A (es)
MY (1) MY117109A (es)
NO (1) NO315734B1 (es)
NZ (2) NZ320545A (es)
OA (1) OA10697A (es)
PE (1) PE25798A1 (es)
PL (1) PL186795B1 (es)
PT (1) PT868183E (es)
RS (1) RS49523B (es)
RU (1) RU2141827C1 (es)
SI (1) SI0868183T1 (es)
SK (1) SK284412B6 (es)
TN (1) TNSN96163A1 (es)
TW (1) TW449475B (es)
UA (1) UA56151C2 (es)
WO (1) WO1997023217A1 (es)
ZA (1) ZA9610780B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
WO2002053136A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Preparations a liberation soutenue
MXPA05000011A (es) * 2002-06-26 2005-04-08 Pharmacia Corp Formulacion parenteral liquida estable de parecoxib.
AU2005258398A1 (en) * 2004-07-02 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Quinolone-containing medicinal composition
KR101488403B1 (ko) * 2005-05-18 2015-02-04 엠펙스 파마슈티컬즈, 인코포레이티드 에어로졸화된 플루오로퀴놀론 및 이의 용도
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
RU2008136460A (ru) * 2006-02-10 2010-03-20 Пари Фарма ГмбХ (DE) Фармацевтический аэрозоль
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
PL2346509T3 (pl) 2008-10-07 2021-03-08 Horizon Orphan Llc Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc
MX353288B (es) 2009-09-04 2018-01-08 Raptor Pharmaceuticals Inc Uso de levofloxacina aerosolizada para el tratamiento de fibrosis quistica.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
WO2016195020A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2016195014A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
CN110248643B (zh) * 2017-02-13 2023-11-24 拜耳动物保健有限责任公司 含普拉沙星的液体组合物
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
WO1991009525A1 (en) * 1989-12-29 1991-07-11 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0443381B2 (en) * 1990-02-14 1997-10-22 Takeda Chemical Industries, Ltd. Effervescent composition, its production and use
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HRP960607A2 (en) 1998-06-30
RU2141827C1 (ru) 1999-11-27
PL186795B1 (pl) 2004-02-27
DK0868183T3 (da) 2002-03-25
NZ501160A (en) 2001-10-26
US5811130A (en) 1998-09-22
TW449475B (en) 2001-08-11
SI0868183T1 (en) 2002-04-30
BG102542A (en) 1999-06-30
BG63933B1 (bg) 2003-07-31
YU69096A (sh) 1999-06-15
SK284412B6 (sk) 2005-03-04
NO315734B1 (no) 2003-10-20
CZ293747B6 (cs) 2004-07-14
CA2239352A1 (en) 1997-07-03
MY117109A (en) 2004-05-31
SK80798A3 (en) 1999-09-10
AR005147A1 (es) 1999-04-14
PE25798A1 (es) 1998-05-21
AP9600898A0 (en) 1997-01-31
EP0868183B1 (en) 2002-01-30
AU7328996A (en) 1997-07-17
DE69618987D1 (de) 2002-03-14
EG24071A (en) 2008-05-11
CN1205636A (zh) 1999-01-20
IL124454A (en) 2003-10-31
MX9805026A (es) 1998-09-30
BR9612230A (pt) 1999-07-13
EP0868183A1 (en) 1998-10-07
UA56151C2 (uk) 2003-05-15
NZ320545A (en) 2000-03-27
NO982842D0 (no) 1998-06-19
IL124454A0 (en) 1998-12-06
RS49523B (sr) 2006-10-27
TNSN96163A1 (fr) 2005-03-15
ATE212551T1 (de) 2002-02-15
DE69618987T2 (de) 2002-11-21
ZA9610780B (en) 1998-06-22
JPH11501331A (ja) 1999-02-02
DZ2146A1 (fr) 2002-10-23
WO1997023217A1 (en) 1997-07-03
JP3416145B2 (ja) 2003-06-16
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
CO4480098A1 (es) 1997-07-09
MA24035A1 (fr) 1997-07-01
PT868183E (pt) 2002-06-28
GT199600098A (es) 1998-06-12
CA2239352C (en) 2002-06-04
KR100402570B1 (ko) 2003-12-18
IS2010B (is) 2005-05-13
HRP960607B1 (en) 2002-06-30
IS4755A (is) 1998-05-25
KR19990076617A (ko) 1999-10-15
CN1104899C (zh) 2003-04-09
NO982842L (no) 1998-06-19
HUP9903726A3 (en) 2001-01-29
HUP9903726A2 (hu) 2000-04-28
CZ193098A3 (cs) 1999-05-12
OA10697A (en) 2001-05-04
HU227918B1 (en) 2012-06-28
PL328001A1 (en) 1999-01-04

Similar Documents

Publication Publication Date Title
ES2167609T3 (es) Formulaciones de quinolona inyectables.
ES2172944T3 (es) Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
NO931766L (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
NO985964L (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
ES2188663T3 (es) Uso de productos que contienen magnesio para el tratamiento o profilaxis de enfermedades neoplasicas o autoinmunes.
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
PA8531601A1 (es) Nuevos heteroaromatos
BR9810996A (pt) Composição farmacêutica
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
UY24556A1 (es) Comprimidos con alto contenido de famciclovir
ES2085656T3 (es) Forma de administracion peroral de medicamentos peptidicos, en particular insulina.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.